Global Intravenous Immunoglobulin Market - 2020-2027

Market Overview

Immunoglobulin refers to the breakdown of blood plasma that contains antibodies. Intravenous immunoglobulin (IVIG) is defined as a blood product administered intravenously. This therapy is for individuals who cannot produce an adequate number of antibodies. Intravenous immunoglobulin therapy treats patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia, and other forms of hypogammaglobulinemia.

The global intravenous immunoglobulin market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

Factors such as fast changing lifestyles such as sedentary habits, including consumption of salt, sugars and saturated fats, reduced physical activities, and increase in alcohol consumption has led to risinf prevalence of diseases such as acquired and primary immunodeficiency diseases. IVIG therapies being one of the most effective & the only available treatment option for such diseases is anticipated to fuel the intravenous immunoglobulin market growth during the forecast period.

The demand for for the treatment of is rapidly increasing as it is the. The increasing prevalence of lifestyle-associated disorders such as obesity & antibody deficiency disorders are the factors

Increase in primary immune deficiency diseases to drive the intravenous immunoglobulin market

Increasing cases of primary immune deficiency diseases is expected to drive the demand for fast, accurate, and safe treatment options, thus augmenting the market growth. Furthermore, Increasing occorance of dieseases, such as organ transplantation, neurological disorders, peripheral neuropathies, and Alzheimer's disease are expected to provide growth opportunities to the intravenous Immunogl (IVIG) market players. Thus, growing cases of the aforementioned diseases are expected to increase the penetration of IVIG during the forecast period.

Increase in Research and Development

Many companies are actively involved in R&D for the development of innovative drugs and discovering new therapeutic areas for the existing drugs. In August 2017, Kedrion Biopharma, Inc. and Kamada Ltd. received approval from the U.S. FDA for their new product KEDRAB. Promeinent industry players are emphesizing in the development of new plasma collection centers and other collaborative strategies to expand their geographical reach and widen their product portfolio.

COVID-19 Impact Analysis

COVID-19 pandemic affected the global economy in many terms, such as directly affecting production and demand, supply chain disruption, and financial impact. COVID-19 has impacted the manufacturers' supply chain across the globe and shut down the production facilities to minimize the risk of virus spread. Also, the pandemic is expected to have a positive impact on the growth of the intravenous immunoglobulin market globally. The market for immunoglobulin therapies is expected to spike during the pandemic and, thus drive the intravenous immunoglobulin market during the forecast period.

Segment Analysis

Based on the application, the Intravenous Immunoglobulin market has been classified into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.

Hypogammaglobulinemia segment is forecasted for largest market share

The hypogammaglobulinemia segment is the highest contributor to the global market, and is anticipated to maintain its dominance throughout the forecast period. This is mainly attributed to a significant rise in the prevalence of hypogammaglobulinemia disorder across the globe over the years.

Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held significant Market share

Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held significant market share in the application segment of intravenous immunoglobulin market during the forecast period. It is found in patients with diabetes mellitus. The treatment of CIPD involves the usage of immunosuppressive drugs, plasmapheresis and steroids. IVIG is an effective alternative to these methods. The associated benefits such as safety, minimally invasive and user-friendly treatment option are few other factors contributing towards the development of the industry.

Geographical Analysis

Based on geography, the study analyzes the yeast extract market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America is expected to maintain its dominance in the global intravenous immunoglobulin market through the forecast period. Increasing healthcare expenditure, increasing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and the rising inclination of clinicians towards immunodeficiency therapies are major factors attributing to the market growth. Additionally, growing occurrences of primary immunodeficiency (PID) are also expected to drive market growth in the North American region.

The Asia Pacific is expected to show significant growth during the forecast period due to the increasing awareness and potential opportunities for the adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies. Furthermore, the growing geriatric population in the region will augment the market growth.

Competitive Landscape

The global intravenous immunoglobulin market is fiercely competitive with the presence of several large and small players operating in the market. These market players acquire promising companies to expand in the fast-growing markets, focusing on improving their market performance. The key intravenous immunoglobulin players which are contributing to the growth of the global market are Bharat Serums and Vaccines Limited, Biotest AG, China Biologic Products, Inc., Guizhou Taibang Biological Products Co., Ltd, CSL Limited, Grifols, S.A., Hualan Biological Engineering Inc., Kedrion S.p.A., LFB Group, Octapharma AG.

Bharat Serums and Vaccines Limited

Overview: Bharat Serums and Vaccines Limited is one of the fastest growing bio pharmaceutical companies in India. BSV offers products in the areas of gynecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, hematology, and urology. The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Africa. The Company's specialty is in Injectables, Novel Drug Delivery, R&D, Biologicals, Clinical Research, and Biotech.

Product Portfolio: The company's products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins.

Why Purchase the Report?

• Visualize the yeast extract market segmentation composition by route of administration, clinical trial type phase, application, end user and region, highlighting the critical commercial assets and players.
• Identify commercial opportunities in the yeast extract market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of yeast extract market - level 4 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global intravenous immunoglobulin market report would provide access to an approx. 60 market data table, 72 figures and 270 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Table of Contents

1. Global Intravenous Immunoglobulin Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Intravenous Immunoglobulin Market - Market Definition and Overview

3. Global Intravenous Immunoglobulin Market - Executive Summary

• 3.1. Market Snippet by Route of Administration
• 3.2. Market Snippet by Clinical Trial Type Phase
• 3.3. Market Snippet by End-User
• 3.4. Market Snippet by Application
• 3.5. Market Snippet by Region

4. Global Intravenous Immunoglobulin Market - Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increase in primary immune deficiency diseases to drive the intravenous immunoglobulin market
    • 4.1.1.2. Increase in Research and Development
    • 4.1.1.3. Rise in Geriatric Population.
  • 4.1.2. Restraints:
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Intravenous Immunoglobulin Market - Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Value Chain Analysis
• 5.4. PEST Analysis
• 5.5. Pricing Analysis
• 5.6. Regulatory Analysis
• 5.7. Reimbursement Analysis
• 5.8. Unmet Needs
• 5.9. Patent Trends

6. Global Intravenous Immunoglobulin Market - COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Intravenous Immunoglobulin Market - By Route of Administration

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
• 7.3. Market Attractiveness Index, By Route of Administration Segment
  • 7.3.1. Intravenous*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Subcutaneous

8. Global Intravenous Immunoglobulin Market - By Clinical Trial Type Phase

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase Segment
• 8.3. Market Attractiveness Index, By Clinical Trial Type Phase Segment
  • 8.3.1. Immunoglobulin G*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Immunoglobulin A
  • 8.3.3. Immunoglobulin M
  • 8.3.4. Immunoglobulin E
  • 8.3.5. Immunoglobulin D

9. Global Intravenous Immunoglobulin Market - By End-User

• 9.1. Introduction
• 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
• 9.3. Market Attractiveness Index, By End-User Segment
  • 9.3.1. Hospitals*
    • 9.3.1.1. Introduction
    • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3.2. Clinics
  • 9.3.3. Homecare
  • 9.3.4. Others

10. Global Intravenous Immunoglobulin Market - By Application

• 10.1. Introduction
• 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
• 10.3. Market Attractiveness Index, By Application Segment
  • 10.3.1. Hypogammaglobulinemia*
    • 10.3.1.1. Introduction
    • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3.2. Chronic Inflammatory Demyelinating Polyneuropathy
  • 10.3.3. Immunodeficiency Disease
  • 10.3.4. Myasthenia Gravis
  • 10.3.5. Multifocal Motor Neuropathy
  • 10.3.6. Idiopathic Thrombocytopenic Purpura (ITP)
  • 10.3.7. Inflammatory Myopathies
  • 10.3.8. Specific Antibody Deficiency
  • 10.3.9. Guillain-Barre Syndrome
  • 10.3.10. Others

11. Global Intravenous Immunoglobulin Market - By Region

• 11.1. Introduction
• 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 11.3. Market Attractiveness Index, By Region
• 11.4. North America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. U.S.
    • 11.4.7.2. Canada
    • 11.4.7.3. Mexico
• 11.5. Europe
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. Germany
    • 11.5.7.2. U.K.
    • 11.5.7.3. France
    • 11.5.7.4. Italy
    • 11.5.7.5. Spain
    • 11.5.7.6. Rest of Europe
• 11.6. South America
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.6.7.1. Brazil
    • 11.6.7.2. Argentina
    • 11.6.7.3. Rest of South America
• 11.7. Asia Pacific
  • 11.7.1. Introduction
  • 11.7.2. Key Region-Specific Dynamics
  • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
  • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.7.7.1. China
    • 11.7.7.2. India
    • 11.7.7.3. Japan
    • 11.7.7.4. Australia
    • 11.7.7.5. Rest of Asia Pacific
• 11.8. Middle East and Africa
  • 11.8.1. Introduction
  • 11.8.2. Key Region-Specific Dynamics
  • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Type Phase
  • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12. Global Intravenous Immunoglobulin Market - Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Global Intravenous Immunoglobulin Market - Company Profiles

• 13.1. Bharat Serums and Vaccines Limited*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Biotest AG
• 13.3. China Biologic Products, Inc.
• 13.4. Guizhou Taibang Biological Products Co., Ltd
• 13.5. CSL Limited
• 13.6. Grifols, S.A.
• 13.7. Hualan Biological Engineering Inc.
• 13.8. Kedrion S.p.A.
• 13.9. LFB Group
• 13.10. Octapharma AG

LIST NOT EXHAUSTIVE

14. Global Intravenous Immunoglobulin Market - Premium Insights

15. Global Intravenous Immunoglobulin Market - DataM Intelligence

• 15.1. Appendix
• 15.2. About Us and Services
• 15.3. Contact Us